Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humira in ulcerative colitis (long-term safety)
NCT00573794Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2007
- Primary completion
- Dec 2016
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in ulcerative colitis (UC), sponsored by AbbVie Inc. Primary endpoints: Partial Mayo Score at 388 weeks and Mayo Score at 388 weeks. Started Nov 2007; status: completed.
02
Drugs
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00573794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00573794.